# A Study to Investigate the Safety and Tolerability of a New Inhaled Formulation of RV568 in Healthy Volunteers

> **NCT01661244** · PHASE1 · COMPLETED · sponsor: **Respivert Ltd** · enrollment: 50 (actual)

## Conditions studied

- COPD
- Healthy Volunteers

## Interventions

- **DRUG:** RV568 single dose
- **DRUG:** RV568 matching placebo single dose
- **DRUG:** RV568 repeat dose
- **DRUG:** RV568 matching placebo repeat dose

## Key facts

- **NCT ID:** NCT01661244
- **Lead sponsor:** Respivert Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2013-02
- **Final completion:** 2013-02
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2013-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01661244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01661244, "A Study to Investigate the Safety and Tolerability of a New Inhaled Formulation of RV568 in Healthy Volunteers". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01661244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*